Comment: Thermo Fisher-Olink deal raises questions over competition vs. efficiencies in fast-evolving market
Thermo Fisher Scientific’s planned Olink acquisition may make regulators weigh concerns that innovation could be harmed, against potential efficiencies in the fast-growing market for testing proteins. The US health giant’s proposed $3.1...To view the full article, register now.
Already a subscriber? Click here to view full article